Clinical trials: Palpable Breast Cancer
Breast Cancer
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast).
- Trial name
- NCT00777673
- Testing
- Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Cancer Institute
Breast Cancer
ROLL Versus Magnetic Seed for Preoperative Localization of Non-palpable Breast Lesion: Comparison Between Techniques.
Nowadays, Breast Conservative Surgery (BCS) is the standard of care for patients affected by early breast lesions. Screening programmes led to an increase of impalpable breast lesion detection rates.
- Trial name
- SEED01 (NCT05942092)
- Testing
- Breast conserving surgery
- Where
- Italy
- Volunteers
- 1,400 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Invasive Breast Cancer
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined…
- Trial name
- NCT00486668
- Testing
- doxorubicin, cyclophosphamide, paclitaxel
- Where
- 110 sites in United States, Canada and 1 more
- Volunteers
- 529 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Different Localization Techniques for Non-palpable Breast Lesions Comparison: a Retrospective and Multicentric Clinical Study
Breast conservative surgery (BCS) is nowadays the standard of care for patients affected by early breast lesions. Screening programmes led to an increase of non-palpable breast lesion detection rates.
- Trial name
- Localization01 (NCT05942105)
- Testing
- Breast conservative surgery
- Where
- Italy
- Volunteers
- 1,064 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Breast Cancer
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00408408
- Testing
- bevacizumab, capecitabine, cyclophosphamide
- Where
- 442 sites in United States, Canada and 1 more
- Volunteers
- 1,206 people
- Sponsor
- NSABP Foundation Inc
HER2/Neu Positive, Stage IA Breast Cancer
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
This randomized phase III trial is studying giving fluorouracil together with epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab to see how well it works compared with giving paclitaxel together with…
- Conditions
- HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00513292
- Testing
- Cyclophosphamide, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 115 sites in United States, Puerto Rico
- Volunteers
- 280 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Invasive Nos, Stage 0 Breast Carcinoma
Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers
The purpose of this study is to determine whether a new surgical technique (radioguided seed localization) for localizing nonpalpable breast tumours is better than the standard technique (needle localization).
- Trial name
- NCT00225927
- Testing
- radioguided seed localization for nonpalpable breast cancers
- Where
- 3 sites in Canada
- Volunteers
- 333 people
- Sponsor
- McMaster University
Breast Cancer
"The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"
Rationale: Approximately 25% of breast cancers detected are non palpable. Accordingly, a localization technique is required to help the surgeon to find and remove the cancer.
- Trial name
- ROLL (NCT00539474)
- Testing
- Radio guided occult lesion localisation
- Where
- 4 sites in Netherlands
- Volunteers
- 316 people
- Sponsor
- UMC Utrecht
Breast Cancer
ROLL vs WGLL for Non-palpable Breast Lesions
Here were present a controlled clinical trial comparing wire-guided lesion localization (WGLL)and radioguided occult lesion localization (ROLL) in patients treated for nonpalpable breast lesions at the Instituto Nacional de…
- Trial name
- ROLLvsWGLL (NCT02869230)
- Testing
- ROLL, wire-guided lesion localization
- Volunteers
- 129 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Breast Diseases, Breast Cancer
Effectiveness and Safety of Preoperative Magnetic Detection of Non-palpable Breast Lesions
Breast cancer is the most common cancer in women and also has the highest death rate. In 2018, 58,500 new cases were diagnosed in metropolitan France. It affects, in 8 out of 10 cases, women aged 50 and over.
- Trial name
- MAGREES (NCT05327218)
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Breast Neoplasm Female
Breast Localization: RFID Tags vs Wire Localization
The RFID trial focuses on breast localization in patients with non-palpable breast cancers. It aims to demonstrate the improvement in patient comfort when using the Radio Frequency Identification (RFID) tag and LOCalizer™ device…
- Trial name
- RFID (NCT04750889)
- Testing
- RFID tags, Wire localization
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Jean Perrin
Breast Cancer, Breast-conserving Surgery
Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy
The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs.
- Trial name
- NCT05838001
- Testing
- Wire-guided localization and marker clip localization, marker clip localization
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University